Sathekge, Mike MachabaLawal, Ismaheel OpeyemiBal, ChandrasekharBruchertseifer, FrankBallal, SajanaCardaci, GiuseppeDavis, CindyEiber, MathiasHekimsoy, TürkayKnoesen, OttoKratochwil, ClemensLenzo, Nat P.Mahapane, JohncyMaserumule, Letjie C.Mdlophane, Amanda H.Mokoala, Kgomotso M.G.Ndlovu, HonestPant, VineetRathke, HendrikReed, Janet D.Sen, Ishita B.Singh, AviralSood, AshwaniTauber, RobertThakral, ParulYadav, Madhav PrasadMorgenstern, Alfred2025-09-082025-09-082024-02Sathekge, M.M., Lawal, I.O., Bal, C. et al. 2024, 'Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act) : a multicentre, retrospective study', Lancet Oncology, vol. 25, no. 2, pp. 175-183, doi : 10.1016/S1470-2045(23)00638-1.1470-2045 (print)1474-5488 (online)10.1016/S1470-2045(23)00638-1http://hdl.handle.net/2263/104248DATA SHARING : The de-identified individual-level patient data, data dictionary, and protocol for this study can be provided to researchers upon written request 24–36 months after publication of the Article. Please send enquiries to the corresponding author. A detailed proposal for how the data will be used is required and we will assess applications on a case-by-case basis, and only for the purpose of individual participant data meta-analysis. A data access agreement must be signed for these data to be released.Please read abstract in the article.en© 2024 All rights are reserved, including those for text and data mining, AI training, and similar technologies, including those for text and data mining, AI training, and similar technologies. Notice : this is the author’s version of a work that was accepted for publication in Lancet Oncology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in Lancet Oncology, vol. 25, no. 2, pp. 175-183, 2024, doi : 10.1016/S1470-2045(23)00638-1.Prostate-specific membrane antigen (PSMA)Actinium-225Radioligand therapy (RLT)Metastatic castration-resistant prostate cancer (mCRPC)SafetyAntitumour activityPostprint Article